Document is current
Any future updates will be listed below
-
Authors
Kramer, Gero
Shore, Neal
Joshua, Anthony
Li, Xin Tong
Poehlein, Christian
Schloss, Charles
Bono, Johann De
Yu, Evan
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02861573 at ClinicalTrials.govnct02861573 at ClinicalTrials.govDocuments that mention this clinical trial
Coformulation of pembrolizumab and vibostolimab in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort G.
https://doi.org/10.1200/jco.2024.42.4_suppl.149
351 KEYNOTE-365 cohort D: pembrolizumab plus abiraterone acetate and prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC)
https://doi.org/10.1136/jitc-2021-sitc2021.351
Pembrolizumab (pembro) plus lenvatinib (lenva) in patients (pts) with docetaxel-pretreated, metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort E.
https://doi.org/10.1200/jco.2024.42.4_suppl.148
344 Phase 3 trial of pembrolizumab and enzalutamide versus enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) (KEYNOTE-641)
https://doi.org/10.1136/jitc-2020-sitc2020.0344
425 Pembrolizumab + vibostolimab in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC: phase 1b/2 KEYNOTE-365 cohorts G/H
https://doi.org/10.1136/jitc-2021-sitc2021.425
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
347 KEYNOTE-365 cohort C: pembrolizumab + enzalutamide in patients with abiraterone acetate–pretreated metastatic castration-resistant prostate cancer (mCRPC)—data after minimum of 22 months of follow-up
https://doi.org/10.1136/jitc-2021-sitc2021.347
346 KEYNOTE-991: phase 3 study of pembrolizumab plus enzalutamide and androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
https://doi.org/10.1136/jitc-2020-sitc2020.0346
Phase 1b/2 study of pembrolizumab plus belzutifan and belzutifan alone in patients with docetaxel-treated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort J.
https://doi.org/10.1200/jco.2024.42.4_suppl.tps250
419 Pembrolizumab + lenvatinib in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC: Phase 1b/2 KEYNOTE-365 cohorts E/F
https://doi.org/10.1136/jitc-2021-sitc2021.419
343 Phase 3 study of pembrolizumab + docetaxel and prednisone/prednisolone for metastatic castration-resistant prostate cancer (mCRPC) pretreated with next-generation hormonal agents (NHAs) (KEYNOTE-921)
https://doi.org/10.1136/jitc-2020-sitc2020.0343
418 Phase 1b/2 KEYNOTE-365 cohort I: platinum-containing chemotherapy alone or in combination with pembrolizumab for treatment-emergent neuroendocrine prostate carcinoma
https://doi.org/10.1136/jitc-2021-sitc2021.418
345 Phase 3 study of combination pembrolizumab + olaparib therapy versus enzalutamide/abiraterone in metastatic castration-resistant prostate cancer (mCRPC) after progression on chemotherapy (KEYLYNK-010)
https://doi.org/10.1136/jitc-2020-sitc2020.0345
Phase 1b/2 study of pembrolizumab (pembro) plus platinum/etoposide and platinum/etoposide for neuroendocrine metastatic prostate cancer (NEPC): KEYNOTE-365 cohort I.
https://doi.org/10.1200/jco.2024.42.4_suppl.tps249
Documents that mention this clinical trial
Coformulation of pembrolizumab and vibostolimab in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort G.
https://doi.org/10.1200/jco.2024.42.4_suppl.149
351 KEYNOTE-365 cohort D: pembrolizumab plus abiraterone acetate and prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC)
https://doi.org/10.1136/jitc-2021-sitc2021.351
Pembrolizumab (pembro) plus lenvatinib (lenva) in patients (pts) with docetaxel-pretreated, metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort E.
https://doi.org/10.1200/jco.2024.42.4_suppl.148
344 Phase 3 trial of pembrolizumab and enzalutamide versus enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) (KEYNOTE-641)
https://doi.org/10.1136/jitc-2020-sitc2020.0344
425 Pembrolizumab + vibostolimab in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC: phase 1b/2 KEYNOTE-365 cohorts G/H
https://doi.org/10.1136/jitc-2021-sitc2021.425
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
347 KEYNOTE-365 cohort C: pembrolizumab + enzalutamide in patients with abiraterone acetate–pretreated metastatic castration-resistant prostate cancer (mCRPC)—data after minimum of 22 months of follow-up
https://doi.org/10.1136/jitc-2021-sitc2021.347
346 KEYNOTE-991: phase 3 study of pembrolizumab plus enzalutamide and androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
https://doi.org/10.1136/jitc-2020-sitc2020.0346
Phase 1b/2 study of pembrolizumab plus belzutifan and belzutifan alone in patients with docetaxel-treated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort J.
https://doi.org/10.1200/jco.2024.42.4_suppl.tps250
419 Pembrolizumab + lenvatinib in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC: Phase 1b/2 KEYNOTE-365 cohorts E/F
https://doi.org/10.1136/jitc-2021-sitc2021.419
343 Phase 3 study of pembrolizumab + docetaxel and prednisone/prednisolone for metastatic castration-resistant prostate cancer (mCRPC) pretreated with next-generation hormonal agents (NHAs) (KEYNOTE-921)
https://doi.org/10.1136/jitc-2020-sitc2020.0343
418 Phase 1b/2 KEYNOTE-365 cohort I: platinum-containing chemotherapy alone or in combination with pembrolizumab for treatment-emergent neuroendocrine prostate carcinoma
https://doi.org/10.1136/jitc-2021-sitc2021.418
345 Phase 3 study of combination pembrolizumab + olaparib therapy versus enzalutamide/abiraterone in metastatic castration-resistant prostate cancer (mCRPC) after progression on chemotherapy (KEYLYNK-010)
https://doi.org/10.1136/jitc-2020-sitc2020.0345
Phase 1b/2 study of pembrolizumab (pembro) plus platinum/etoposide and platinum/etoposide for neuroendocrine metastatic prostate cancer (NEPC): KEYNOTE-365 cohort I.
https://doi.org/10.1200/jco.2024.42.4_suppl.tps249
